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TP-expressing cancer cells, thymidine
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Thymidine phosphorylase (TP), a rate-limiting en-
zyme in thymidine catabolism, plays a pivotal role
in tumor progression; however, the mechanisms un-
derlying this role are not fully understood. Here, we
found that TP-mediated thymidine catabolism could
supply the carbon source in the glycolytic pathway
and thus contribute to cell survival under conditions
of nutrient deprivation. In TP-expressing cells,
thymidine was converted to metabolites, including
glucose 6-phosphate, lactate, 5-phospho-a-D-
ribose 1-diphosphate, and serine, via the glycolytic
pathway both in vitro and in vivo. These thymidine-
derived metabolites were required for the survival
of cells under low-glucose conditions. Furthermore,
activation of thymidine catabolism was observed in
human gastric cancer. These findings demonstrate
that thymidine can serve as a glycolytic pathway
substrate in human cancer cells.INTRODUCTION
Thymidine phosphorylase (TP) catalyzes the reversible phospho-
rolysis of thymidine to thymine and 2-deoxy-D-ribose 1-phos-
phate (DR1P). We have previously demonstrated that TP is
identical to the angiogenic factor platelet-derived endothelial
cell growth factor (PD-ECGF) (Furukawa et al., 1992). TP expres-
sion in various malignant tumors is higher than in adjacent non-
neoplastic tissues (Takebayashi et al., 1996b), and a poor
prognosis is associated with TP-positive versus TP-negativeCell
This is an open access article under the CC BY-Ncolon and differentiated gastric carcinomas (Shimaoka et al.,
2000; Takebayashi et al., 1996a).
2-Deoxy-D-ribose (DR) is a downstream mediator of TP
function; it also shows angiogenic activity and shares some
functions with TP (Haraguchi et al., 1994). DR affects endothelial
cell migration through activation of the integrin downstream
signaling pathway (Hotchkiss et al., 2003). Conversely, rapamy-
cin completely abrogates DR-induced cell migration and angio-
genesis via inhibition of DR-induced p70/s6 kinase activation
(Seeliger et al., 2004). DR and DR1P are enzymatically converted
to 2-deoxy-D-ribose 5-phosphate (DR5P) (Hoffee, 1968); both
DR1P and DR5P accumulate at high levels in TP-overexpressing
cells, which extensively secrete DR (Bijnsdorp et al., 2010). How-
ever, the functional cascades induced by TP and DR remain
largely unknown.
RESULTS
Growth Advantage Conferred by TP under Low-Nutrient
Conditions
Animal models and clinical studies have shown that TP is
involved in cancer cell growth, invasion, and metastasis
(Akiyama et al., 2004). We found that, in a xenograft mouse
model, TP-overexpressing human epidermoid carcinoma KB
(KB/TP) cells demonstrated a growth advantage over TP-nega-
tive control vector-transfected (KB/CV) cells and that KB/TP
cell growth was suppressed by TPI, a TP enzymatic inhibitor
(Matsushita et al., 1999). Figure S1A and Figure 1A show the
growth of KB cells in 10% fetal bovine serum (FBS) and
serum-free medium, respectively. Under serum-free conditions,
both cell types had a similar growth rate until 2 days, whereas the
growth of KB/CV cells, but not KB/TP cells, was suppressed








(legend on next page)
1314 Cell Reports 19, 1313–1321, May 16, 2017
those of KB/CV and KB/TPmut cells, which express an enzy-
matic activity-deficient mutant TP (Figure 1A). The sub-G1 frac-
tion, a measure of apoptosis, was considerably lower in KB/TP
cells than in KB/CV cells under serum-free conditions (Fig-
ure S1B). These results suggested that TP enzymatic activity
provides a growth advantage for KB/TP cells under low-nutrition
conditions.
2-Deoxy-D-glucose (2-DG), a glucose analog, inhibits phos-
phohexose isomerase and restricts glucose availability. In a col-
ony formation assay, KB/TP cells were more resistant to 2-DG
than KB/CV cells (Figure 1B), as were TP-overexpressing (EJ/
TP) versus control-transfected (EJ/CV) human bladder carci-
noma EJ cells (Figure S1C). Although 300 mM TPI did not affect
KB/CV and KB/TP colony formation, it significantly decreased
KB/TP colony number in the presence of 1.5 mM 2-DG (Fig-
ure 1C). TPI also considerably enhanced the cytotoxic effect of
2-DG against intrinsically TP-expressing human cervical cancer
Yumoto cells (Figure 1D). We also assessed the consumption
levels of glucose and glutamine in KB cells under serum-free
conditions (Figure S1D). Glucose and glutamine levels in KB/
TP cell culturemediumwere similar to those in KB/CV cell culture
medium. These results suggest that TP contributes to cell growth
specifically under glucose deprivation conditions and that the
growth advantage in KB/TP cells is not related to glucose and
glutamine uptake.
Thymidine Catabolism as the Carbon Source for
Glycolysis in TP-Expressing Cancer Cells
In certain prokaryotes, phosphopentose mutase (PPM) converts
thymidine-derived DR1P to DR5P, which is then converted to
glyceraldehyde 3-phosphate (GAP) and acetaldehyde by DR5P
aldolase (DERA) (Hoffee, 1968). Given that GAP is an intermedi-
ate in the glycolytic pathway and pentose phosphate pathway
(PPP), we hypothesized that the activation of thymidine catabo-
lism by TP could supply the carbon source for those pathways.
However, the thymidine catabolic pathway in mammalian cells
remains unclarified. We examined whether 10,20,30,40,50-13C5-
thymidine (13C5-thymidine) metabolites (Figure S2A) enter the
glycolytic pathway and PPP in KB/TP cells. An expected 13C5-
thymidine catabolic pathway is shown in Figure 1E. The time-
dependent accumulation of 13C-metabolites (DR5P, lactate,
and 5-phospho-a-D-ribose 1-diphosphate [PRPP]) in KB/TP
cells treated with 13C5-thymidine were determined (Figure 1F).
Figure S2B shows the enrichment of 13C-metabolites in the
same experiments. We also detected 13C1- and
13C2-labeledFigure 1. Growth Advantage by TP under Low-Nutrient Conditions
(A) Growth curves for KB/CV, KB/TP, and KB/TPmut cells in serum-free medium
(B) Colony-forming abilities of KB/CV and KB/TP cells. Shown are representativ
pendent experiments (right).
(C) Effect of TPI on KB/CV and KB/TP colony formation in the absence or presen
(D) Cytotoxic effect of 2-DG with or without TPI on Yumoto cells incubated in se
(E) Catabolic pathway of 13C5-thymidine.
(F) KB/CV and KB/TP cells were incubated in serum-free medium with 500 mM
determined using CE-MS.
(G) KB/TP cells were treated with 500 mM 13C5-thymidine for 1 hr after the cells w
(H) KB/TP cells transfected with DERA siRNA were treated with 500 mM 13C5-thy
(I) Effect of DERA knockdown on the survival of KB cells incubated for 4 days un
Data are represented as the means ± SD. *p < 0.01, **p < 0.05.metabolites in the lactate and PRPP of KB/CV cells, which
were expected to be natural. Because the limited 13C-metabo-
lites were recognized (Figure 1F), we further examined whether
the other 13C-labeled glycolytic intermediates could be detected
in KB/TP cells when the experimental conditions were changed.
13C3-G6P was detected as early as 10 min after
13C5-thymidine
addition (Figure S2C). In KB/TP cells treated with 13C5-thymidine
for 1 hr under 80%–90% confluent conditions after the cells had
been pre-cultured for 72 hr in DMEM containing 10% FBS,
13C3-labeled downstream metabolites of glycolysis (GAP, dihy-
droxyacetone phosphate [DHAP], 2,3-bisphosphoglyceric acid
[2,3BPG], 3-phosphoglyceric acid [3PG], 2-phosphoglyceric
acid [2PG], and phosphoenolpyruvate [PEP]) were detected
(Figure 1G). Thymidine-derived metabolites (13C5-DR5P and
13C3-lactate) also accumulated in endogenous TP-expressing
pancreatic cancer Panc1 and Yumoto cells (Figure S2D); the
accumulation was suppressed upon TP small interfering RNA
(siRNA) knockdown (Figure S2D). Although the pattern of
13C-labeled metabolites varies depending on 13C5-thymidine
tracing times, cell culture conditions, or cell types, these results
demonstrated that thymidine catabolism can act as a carbon
source for glycolytic intermediates. Notably, 13C2-N-acetylas-
partic acid and 13C2-N-acetylglutamic acid were observed in
13C5-thymidine-treated KB/TP cells (Figure S2E), and DR5P-
derived acetaldehyde is expected to react with amino acids to
generate N-acetylamino acids. In 13C2-acetaldehyde-treated
KB/TP cells, the 13C2-labeled N-acetylamino acid was detected
(Figure S2F). These results strongly suggest that 13C5-DR5P is
converted to 13C3-GAP and
13C2-acetaldehyde by DERA.
DERA is a key enzyme in the pathway by which thymidine-
derived DR5P enters the glycolytic pathway (Figure 1E). We
examined the effect of DERA downregulation (Figure S2G) on
13C-labeled DR5P in 13C5-thymidine-treated KB/TP cells and
the growth of KB/CV and KB/TP cells under serum-free condi-
tions. siRNA-mediated DERA knockdown increased 13C5-
DR5P accumulation (Figure 1H) and significantly reduced viable
in KB/TP cells cultured for 4 days under serum-free conditions
(Figure 1I).
Utilization of Thymidine in KB Cells in Different
Nutritional States
As shown in Figure 1A, the growth rates of KB cells cultured for
4–6 days in serum-freemedium declined. The glucose and gluta-
mine levels in the KB cell culture medium at 4 and 6 days were
conspicuously lower than those in fresh medium (Figure S1D).with or without 300 mM TPI.
e culture plates (left) and average colony counts calculated from three inde-
ce of 1.5 mM 2-DG.
rum-free medium in the absence or presence of TPI and/or 2-DG for 6 days.
13C5-thymidine for the indicated times;
13C-labeled metabolite levels were
ere pre-cultured in DMEM containing 10% FBS for 72 hr.
midine for 1 hr; intracellular 13C-labeled DR5P was determined.
der serum-free conditions.
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Figure 2. Metabolic Analysis of 13C-Metabolites after Addition of 13C5-Thymidine under Low-Nutrition Conditions
(A) KB/CV and KB/TP cells were treated with 500 mM13C5-thymidine for the indicated times after the cells were pre-cultured in serum-freemedium for 1 or 4 days.
13C-metabolite levels were determined using CE-MS.
(B) Catabolic pathway for 13C5-DR.
(C) KB/CV cells were incubated in serum-free medium with 1 mM 13C5-DR for 1 hr;
13C-labeled metabolite levels were determined using CE-MS.
Data are represented as the means ± SD.To examine thymidine catabolism in KB cells under low-nutri-
tion conditions, we analyzed the 13C5-thymidine-derived me-
tabolites in KB cells pre-cultured with serum-free medium for
1 or 4 days. Figure 2A shows the time-dependent accumulation
of 13C5-thymidine and the thymidine-catabolized
13C-metabo-
lites (DR5P, lactate, and serine [Ser]) in KB cells treated with
13C5-thymidine for the indicated times. Figure S3A indicates
the enrichment of 13C-metabolites in the same experiments.
13C5-DR5P,
13C3-lactate, and
13C3-Ser were detected in KB/
TP but not KB/CV cells. In KB/TP cells pre-cultured with
serum-free medium for 4 days, 13C5-thymidine was mainly
metabolized to 13C3-Ser. The
13C3-Ser levels were suppressed
by DERA siRNA (Figure S3B). Ser is derived from the glycolytic
intermediate 3-phosphoglyceric acid via a three-step reaction1316 Cell Reports 19, 1313–1321, May 16, 2017and contributes to the survival of cancer cells (Yang and Vous-
den, 2016). This result implies that the thymidine-derived Ser
serves the survival of KB/TP cells under low-nutrition condi-
tions. Furthermore, we examined the 13C-labeled thymidine
phosphates (thymidine monophosphate [dTMP], thymidine
diphosphate [dTDP], and thymidine triphosphate [dTTP]) to
assess the utilization of 13C5-thymidine for DNA synthesis in
KB cells. (Figures 2A and S3A). The total 13C-metabolite levels
in dTMP, dTDP, and dTTP in KB/CV and KB/TP on day 4 were
lower than those on day 1. Furthermore, the 13C-metabolite
levels in KB/TP on day 4 were lower than those in KB/CV on
day 4. These results suggest that thymidine catabolism is
needed for the survival of cancer cells under low-nutrition
conditions.
Incorporation of Non-phosphorylated DR in Non-TP-
Expressing Cancer Cells
Non-phosphorylated DR is secreted by TP-expressing cells,
promotes endothelial and cancer cell migration (Bijnsdorp
et al., 2010; Hotchkiss et al., 2003; Nakajima et al., 2004), and
can be converted to DR5P by DR kinase in Salmonella typhimu-
rium (Hoffee, 1968). We examined whether 13C-labeled DR
(13C5-DR) was converted to DR5P and consequently entered
glycolysis in TP-negative cell lines: KB/CV, human umbilical
vein endothelial cells (HUVECs), and human fibroblast MRC5
cells. Figure 2B shows the expected 13C5-DR catabolic pathway.
13C5-DR5P and
13C3-lactate were detected in KB/CV cells
treated for 1 hr (Figure 2C) but not in HUVECs and MRC5 cells
(data not shown). These results suggest that DR secreted from
TP-expressing cells is incorporated into adjacent, non-TP-ex-
pressing cancer cells as a carbon source for glycolysis. We
also considered that the uptake or metabolism of DR might
vary by cell type.
Metabolic Alterations by TP under Physiological
Conditions
We next examined whether TP-mediated thymidine catabolism
affects glycolytic pathway intermediates under physiological
conditions. Previously, we established TP and uridine phosphor-
ylase (UP) double knockout (TP-UP DKO) mice (because murine
UP also exhibits TP activity) to abolish TP enzymatic activity
(Haraguchi et al., 2002). We performed a metabolome analysis
of the livers, which exhibit high TP activity (Haraguchi et al.,
2002), from wild-type (WT) and TP-UP DKO mice, identifying
and quantifying 236 metabolites (Table S1). Principal-compo-
nent analysis (PCA) demonstrated differing characteristic pat-
terns of metabolites levels in TP-UP DKO versus WT mouse
livers (Figure 3A), with 56 differing significantly (Figure S4A).
Metacore software analysis identified 10 canonical pathways
that differed significantly between groups (Figure 3B); in partic-
ular, glycolysis and its adjacent pathways, including PPP and
the tricarboxylic acid (TCA) cycle, were affected by TP. Hierar-
chical clustering heatmap analysis of glycolysis intermediates
also showed different clustering between WT and TP-UP DKO
mice (Figure 3C) and indicated significant changes in themajority
of the intermediates (Figure S4B). We also tested whether 13C5-
thymidine was converted to glycolytic pathway intermediates in
xenografted TP-expressing Yumoto cells and in the spleen and
liver of tumor-bearing mice because high TP activity was de-
tected in the liver but not in the spleen (Haraguchi et al., 2002).
Figure 3D shows the 13C5-thymidine concentrations in whole
blood harvested 0, 3, and 10 min following tail vein injection in
themice.We identified higher 13C5-thymidine levels in the spleen
than in the liver and tumor tissues (Figure 3E, left) and the
converse effect for 13C3-lactate (Figure 3E, right). We also per-
formed 13C5-thymidine trace experiments in TP-UP DKO and
WT mouse livers. The livers were harvested 3 min after 13C5-
thymidine injection. The 13C5-thymidine levels in TP-UP DKO
mouse livers were higher than those inWTmouse livers, whereas
13C3-lactate exhibited the opposite trend (Figure 3F). These re-
sults demonstrate that thymidine-derived metabolites enter the
glycolytic pathway in a physiological context and that thymidine
catabolism depends on TP activity.Levels of Thymidine and Phosphorylated Deoxyribose in
Human Gastric Cancer
We reanalyzed our previously reported gastric cancer tissueme-
tabolome data (Hirayama et al., 2009) and compared thymidine
and phosphorylated deoxyribose (DR1P plus DR5P [DRP]) levels
in tumor versus adjacent non-neoplastic tissues. Thymidine
levels were significantly lower in tumors than in adjacent tissues
(Figure 4A, left) and were negatively correlated with DRP, which
showed the opposite pattern (Figures 4A, right, and 4B). These
results suggest that thymidine catabolism activity is higher in tu-
mors than in the adjacent non-neoplastic tissues.
DISCUSSION
Several bacteria can use the 2-deoxy-D-ribosyl moiety of 20-de-
oxyribonucleosides as their sole carbon and energy source. Ge-
netic and biochemical studies using S. typhimurium have shown
that three enzymes, TP, PPM, and DERA, are involved in the
thymidine catabolic pathway (Hoffee, 1968); however, equivalent
mammalian studies are limited. TP/PD-ECGF expression in can-
cer, PPM in mammalian tissues, leukemia, and red blood cells
(Accorsi et al., 1989; Nishida and Miyamoto, 1982), and DERA
in vertebrate liver and numerous cell lines (Sgarrella et al.,
1997) have been observed, implying that thymidine catabolism
might satisfy mammalian cell carbon and energy requirements
as well. In this study, we demonstrated thymidine catabolism
in mammalian cells and its functions in cancer cells. However,
our investigation of the biological implications of thymidine
catabolism in energy metabolism in cancer cells is not yet com-
plete. The tracing experiment of 13C5-thymidine (Figure 2A) sug-
gests that thymidine catabolism contributes to Ser biosynthesis
and, consequently, confers resistance to nutrient starvation. In
the future, we will be focusing on the role of thymidine-derived
Ser in cancer cells.
The TP gene (TYMP) is also known as the causative gene for
mitochondrial neurogastrointestinal encephalopathy (MNGIE)
which is a severe autosomal recessive disease with a particularly
poor prognosis (Hirano et al., 2012; Nishino et al., 1999). Previ-
ous reports suggested that the TP deficiency in MNGIE
increases intracellular thymidine levels and leads to deoxynu-
cleoside triphosphate pool imbalances, which, in turn, cause
mitochondrial DNA instability (Hirano et al., 2012). On the other
hand, we showed that the deficiency in TP enzymatic activity
in mice resulted in alterations in glycolytic intermediates in liver
tissues. These findings might instead represent the key pheno-
type through which the abnormality in glycolysis contributes to
the pathogenesis of MNGIE.
In this study, the observed tumor glucose concentrations were
significantly lower than previously reported (Gatenby et al., 2007)
or in adjacent non-neoplastic gastric tissues (Hirayama et al.,
2009). Elevated thymidine concentrations within the tumor
microenvironment can occur because of necrotic cell DNA hy-
drolysis (Brown et al., 2000), and TP is overexpressed proximal
to necrotic tissue in human breast cancer MD231 xenograft tu-
mors (Griffiths et al., 1997). However, because the gastric cancer
tissues used in this study did not contain necrotic regions, their
thymidine and glucose levels were decreased, whereas their





Figure 3. Thymidine Catabolism to Glycolysis in Physiological Contexts
(A) Score plots of PCA for metabolomics profiles of liver tissues in WT (n = 5) and TP-UP DKO mice (n = 6). Metabolite levels were detected with CE-MS.
(B) The first ten most altered liver tissue metabolic pathways in TP-UP DKO mice. Pathway significance was assessed using p values and FDRs (< 0.05).
(legend continued on next page)
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Figure 4. Thymidine and DRP Levels in Human Gastric Cancer
(A) Thymidine and DRP levels in human gastric cancer tissues and adjacent non-neoplastic tissues detected with CE-MS.
(B) Correlation between thymidine and DRP levels in the tissues.
Data are represented as the means ± SD.results suggest that thymidine-derived DRP is consumed for
glycolysis in tumors and that thymidine catabolism might be
important for cancer cell survival in low-glucose microenviron-
ments close to necrotic areas.
Inhibition of TP activity via agents such as TPI (Matsushita
et al., 1999) and 6-(2-aminoethyl) amino-5-chlorouracil (Lu
et al., 2009) or compounds that suppress thymidine-derived
metabolite entry into the glycolytic pathway represents a poten-
tial novel anticancer strategy. Lu et al. (2009) reported that the
combination of the vascular endothelial growth factor (VEGF)
trap, a soluble VEGF decoy receptor, and a TP inhibitor exhibited
additive antitumor activity that was significantly greater than
VEGF inhibition alone. Recent studies also demonstrate the
resistance to anti-angiogenic therapies caused by metabolic
symbiosis (Allen et al., 2016; Jiménez-Valerio et al., 2016; Pisar-
sky et al., 2016), suggesting that TP might represent a suitable
target to overcome such resistance.
A randomized phase 3 study of TAS102, a mixture of TPI and
trifluorothymidine (TFT), an anticancer agent (Mayer et al., 2015),
demonstrated improved overall survival and reduced the mortal-
ity of patients with metastatic colorectal cancer. Because TPI is
thought to enhance TFT antitumor effects by inhibiting TP-
dependent TFT degradation, consequently increasing its plasma
levels, it might also abrogate the TP-mediated tumor growth
advantage and angiogenic activity.
EXPERIMENTAL PROCEDURES
Chemicals and Cell Culture
13C5-thymidine and
13C5-2-deoxy-D-ribose were obtained from Omicron
Biochemicals. 13C2-acetaldehyde was obtained fromCambridge Isotope Lab-(C) Heatmap showing the liver tissue glycolytic metabolite levels in WT (n = 5) and
Z score. Red and blue indicate higher and lower levels, respectively, compared
(D) 13C5-thymidine concentrations, measured with CE-MS, in whole-blood sample
each point).
(E) 13C5-thymidine and
13C3-lactate levels in the spleen (n = 7–8), liver (n = 7–8),
(F) 13C5-thymidine and
13C3-lactate levels in the livers from WT (n = 8) and TP-U
Data are represented as the means ± SD. *p < 0.01, **p < 0.05.oratory. 2-Deoxy-D-glucose was purchased from Sigma-Aldrich. Human
epidermoid carcinoma KB, human bladder cancer EJ, human cervical
carcinoma Yumoto, and human pancreatic cancer Panc1 cells were grown
in DMEM (Nissui Seiyaku) containing 10% FBS, 2 mM glutamine, and
100 units/mL penicillin at 37C in a 5% CO2 humidified atmosphere.
Stable Transfection of TP/PD-ECGF cDNA
We previously established the following stable cell lines: KB/CV, KB/TP, KB/
TPmut, EJ/CV, and EJ/TP (Nakajima et al., 2004; Tabata et al., 2012). The
TP/PD-ECGF full-length cDNA plasmid, the TP/PD-ECGF mutant plasmid
(L148R, Leu-148/Arg) (Miyadera et al., 1995), or the empty vector was trans-
fected into KB or EJ cells by electroporation (Potter et al., 1984). After selection
with geneticin, the expression of TP in each clone was determined by immuno-
blot analysis using an anti-TP monoclonal antibody as described previously
(Takebayashi et al., 1996a).
Colony Formation Assay
Cells (23102)were seeded in eachwell of a6-well tissuecultureplate andmain-
tained in DMEM containing 10% FBS. The growth medium was changed every
3 days. After 7–14 days, the number of Giemsa-stained colonies was counted.
Relative colony counts were determined in three separate experiments with
three wells each.
Cell Viability Assays
Equal numbers of cells (1 3 105) in 3 mL culture medium were inoculated in
each well of a 6-well tissue culture plate. Cell viability was assayed by trypan
blue exclusion using a Vi-Cell cell viability analyzer (Beckman Coulter).
Metabolite Quantification in Cells Using CE-MS
Intracellular metabolites were measured by capillary electrophoresis-time of
flight-mass spectrometry (CE-TOFMS) (Agilent Technologies) as previously
described (Uetaki et al., 2015). The data obtained were analyzed using
MasterHands (Sugimoto et al., 2010). The metabolite identities were deter-
mined bymatching their mass-to-charge ratio (m/z) values andmigration times
with those of their standard compounds.TP-UP DKOmice (n = 6). Metabolite levels in each sample were converted to a
with the average (white).
s from tumor-bearing xenograft mice after 13C5-thymidine injection (n = 7–8 for
and tumor tissues (n = 14–16) from the xenograft mice.
P DKO mice (n = 8).
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Metabolome Analysis of the Livers from TP-UP DKO Mice
All animal experimentswere approved by the Institutional Animal Care andUse
Committee of KagoshimaUniversity. The TP-UPDKOmouse strain was estab-
lished previously (Haraguchi et al., 2002). Livers were collected fromWT (n = 5)
and TP-UP DKO female mice (8–10 weeks old) (n = 6) after blood removal. The
excised tissues were immediately frozen in liquid nitrogen and stored at80C
until use. The extraction and quantification of metabolites using capillary elec-
trophoresis-mass spectrometry (CE-MS) were performed as described previ-
ously (Hirayama et al., 2009).
Analysis of Thymidine-Derived Metabolites in TP-UP DKO Mouse
Livers
We utilized 8- to 10-week-old female mice in this study. Livers were extracted
from WT (n = 8) and TP-UP DKO mice (n = 6) injected with 13C5-thymidine
(100 mg/kg intravenously [i.v.]). The livers were harvested 3 min after the
13C5-thymidine injections. The excised livers were immediately frozen in liquid
nitrogen and stored at 80C until use. The extraction and quantification of
metabolites using CE-MS were performed as described previously (Hirayama
et al., 2009).
Xenograft Studies
Yumoto cells (1 3 106) were injected subcutaneously into both flanks of 6- to
8-week-old female athymic nude mice (CLEA Japan). After 4 weeks, whole
blood, spleens, livers, and tumors were extracted from tumor-bearing mice in-
jected with 13C5-thymidine (100 mg/kg i.v.). The blood and tissues were har-
vested 0, 3, and 10min after the 13C5-thymidine injections. The excised tissues
were immediately frozen in liquid nitrogen and stored at 80C until use. The
extraction and quantification of metabolites using CE-MS were performed as
described previously (Hirayama et al., 2009).
Metabolite Quantification of Gastric Cancer Tissues Using CE-MS
We reanalyzed the levels of thymidine and DRP in gastric cancer tissues using
our previously reported MS datasets (Hirayama et al., 2009). Samples were
removed surgically at the National Cancer Center Hospital East; tumor and
surrounding grossly normal-appearing tissues were collected after informed
consent had been obtained from the patients according to the study protocol
approved by the Institution Review Board of the National Cancer Center. The
patient information and the tumor stages were described previously (Hirayama
et al., 2009). The excised tissues were cut into <1-cm3 pieces, immediately
frozen in liquid nitrogen, and stored at 80C until use. The extraction and
quantification of metabolites using CE-MS were performed as described pre-
viously (Hirayama et al., 2009).
PCA and Heatmap Visualization
Principle-component analysis (PCA) and heatmap visualization were per-
formed as described previously (Saito et al., 2013). PCA, which is a type of un-
supervised statistical analysis used widely as a statistical tool in metabolomics
studies, was applied prior to the detailed data analysis (Sugimoto et al., 2012).
We also visualized the glycolytic metabolites levels as a heatmap representa-
tion and performed hierarchical clustering analysis using a Pearson correla-
tion. JMP version 9.0.2 (SAS Institute) and Mev TM4 software (version 4.7.4.,
Dana-Farber Cancer Institute) were used for PCA and heatmap analysis,
respectively.
Pathway Analysis
The significantly altered metabolites (p < 0.05 with a false discovery rate [FDR]
of 0.05) were analyzed for pathway enrichment using MetaCore (Genego)
(Schuierer et al., 2010; Trushina et al., 2013). The pathway maps in MetaCore
are defined metabolic cascades that have been experimentally validated and
are widely accepted. Metabolite identifiers (Kyoto Encyclopedia of Genes and
Genomes [KEGG] ID and compound name) were used for each metabolite.
The p value from the hypergenometric test, generated by MetaCore, repre-
sents the enrichment of a certain metabolite in a pathway. p < 0.05 is indicative
of significant enrichment. The ratio of altered metabolites in the pathway to the
total number of metabolites in a pathway was also calculated. An FDR of 0.05
was also applied for pathway enrichment.1320 Cell Reports 19, 1313–1321, May 16, 2017Statistical Analysis
Data were analyzed using GraphPad Prism v5.0 software. In in vitro
experiments, data for two groups and more than two groups were
analyzed using Student’s t test and one-way ANOVA, respectively. In mouse
experiments and clinical studies, data for two groups and more than two
groups were analyzed using Mann-Whitney U and Kruskal-Wallis tests,
respectively. The correlation between thymidine and DRP levels in Figure 4B
was analyzed using Spearman’s correlation. The data are presented as
the means ± SD, and differences were considered statistically significant
at p < 0.05.
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